findmyKOL
Clinical trialNCT06601296RecruitingPhase 2Interventional

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

SponsorUniversity of Texas Southwestern Medical CenterEnrollment15Metastatic Renal Cell Carcinoma ( mRCC)OligoProgressive Metastatic Disease
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • RAQUIBUL HANNAN, MD

    University of Texas Southwestern Medical Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Texas Southwestern Medical Center

    Dallas, Texas, United States

    RAQUIBUL HANNAN, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Apr 2025
Primary completion
31 Oct 2027
Completion
31 Oct 2028
Last update posted
12 Nov 2025
Registered enrollment
15
Registry id
NCT06601296

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.